Mutation detail:
| Mutation site | 27137A>T |
| Virus | SARS-CoV-2 |
Mutation level  |
Nucleotide level |
| Gene/protein/region type | M |
| Gene ID | 43740571 |
| Country | - |
| Mutation type |
- |
| Genotype/subtype/clade | 19A |
| Sample |
Human |
| Variants | - |
| Viral reference sequence | MN908947.3 |
| Drug/antibody/vaccine | - |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Membrane Glycoprotein |
| Uniprot protein ID | P0DTC5 |
| Protein length | 222 amino acids |
| Protein description | The membrane protein is present in high amounts out of all proteins in coronaviruses . Its length spans to about 220-260 amino acids with a short length N terminal domain, attached to triple transmembrane domains that are further connected to a carboxyl-terminal domain and belong to the N-linked glycosylated proteins with a conserved domain of 12 amino acids. Out of the three TDM, the first one is capable enough to encourage self-association of M proteins, improved membrane affinity, and retention in Golgi. The membrane protein is a transmembrane glycoprotein, is the most abundant structural protein in the virus particle and has been suggested as an antiviral drug target. |
Literature information:
| Pubmed ID | 34011679 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | mSphere |
| Title | Shedding of Viable Virus in Asymptomatic SARS-CoV-2 Carriers |
| Author | Takayuki Murata,Aki Sakurai,Masahiro Suzuki,Satoshi Komoto,Tomihiko Ide |
| Evidence | Fig. 2 |